Accelerating global innovation to address antibacterial resistance: introducing CARB-X.

Nat Rev Drug Discov

Authors	Kevin Outterson John Rex Tim Jinks Peter Jackson John Hallinan Steve Karp Deborah Hung Francois Franceschi Tyler Merkeley Christopher Houchens Dennis Dixon Michael Kurilla Rosemarie Aurigemma Joseph Larsen
Abstract	A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
Year of Publication	2016
Journal	Nat Rev Drug Discov
Volume	15
Issue	9
Pages	589-90
Date Published	2016 Sep
ISSN	1474-1784
DOI	10.1038/nrd.2016.155
PubMed ID	27469032
Links